(Q34979344)

5 August 2017

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children (English)

1 reference

5 August 2017

0 references

0 references

16

Stanley J Szefler

1 reference

5 August 2017

1

William W Busse

1 reference

5 August 2017

7

Rebecca S Gruchalla

1 reference

5 August 2017

8

Meyer Kattan

1 reference

5 August 2017

Wayne J Morgan

2

1 reference

5 August 2017

Peter J Gergen

3

1 reference

5 August 2017

Herman E Mitchell

4

1 reference

5 August 2017

James E Gern

5

1 reference

5 August 2017

Andrew H Liu

6

1 reference

5 August 2017

Stephen J Teach

9

1 reference

5 August 2017

Jacqueline A Pongracic

10

1 reference

5 August 2017

James F Chmiel

11

1 reference

5 August 2017

Suzanne F Steinbach

12

1 reference

5 August 2017

Agustin Calatroni

13

1 reference

5 August 2017

Alkis Togias

14

1 reference

5 August 2017

Katherine M Thompson

15

1 reference

5 August 2017

Christine A Sorkness

17

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

The New England Journal of Medicine

5 August 2017

1 reference

5 August 2017

364

1 reference

5 August 2017

1005-1015

1 reference

5 August 2017

11

1 reference

Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Role of viral respiratory infections in asthma and asthma exacerbations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Safety and tolerability of omalizumab

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Feasibility of using subject-collected dust samples in epidemiologic and clinical studies of indoor allergens.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Results of a home-based environmental intervention among urban children with asthma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Understanding the seasonal pattern of childhood asthma: results from the National Cooperative Inner-City Asthma Study (NCICAS).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

The minimally important difference of the Asthma Control Test

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Relationship between pretreatment specific IgE and the response to omalizumab therapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Statistics in medicine--reporting of subgroup analyses in clinical trials.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

The September epidemic of asthma exacerbations in children: a search for etiology.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Resistance of differentiated human airway epithelium to infection by rhinovirus

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093964

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

26 October 2018

1 reference

12 December 2020

The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

1 reference

12 December 2020

Understanding the September asthma epidemic

1 reference

12 December 2020

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

12 December 2020

Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists

1 reference

12 December 2020

Development and cross-sectional validation of the Childhood Asthma Control Test

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1009705

1 reference

5 August 2017

1 reference

5 August 2017

1 reference